Literature DB >> 15961398

Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development.

Aldrin V Gomes1, Jingsheng Liang, James D Potter.   

Abstract

Human cardiac Troponin I (cTnI) is the first sarcomeric protein for which mutations have been associated with restrictive cardiomyopathy. To determine whether five mutations in cTnI (L144Q, R145W, A171T, K178E, and R192H) associated with restrictive cardiomyopathy were distinguishable from hypertrophic cardiomyopathy-causing mutations in cTnI, actomyosin ATPase activity and skinned fiber studies were carried out. All five mutations investigated showed an increase in the Ca2+ sensitivity of force development compared with wild-type cTnI. The two mutations with the worst clinical phenotype (K178E and R192H) both showed large increases in Ca2+ sensitivity (deltapCa50 = 0.47 and 0.36, respectively). Although at least one of these mutations is not in the known inhibitory regions of cTnI, all of the mutations investigated caused a decrease in the ability of cTnI to inhibit actomyosin ATPase activity. Mixtures of wild-type and mutant cTnI showed that cTnI mutants could be classified into three different groups: dominant (L144Q, A171T and R192H), equivalent (K178E), or weaker (R145W) than wild-type cTnI in actomyosin ATPase assays in the absence of Ca2+. Although most of the mutants were able to activate actomyosin ATPase similarly to wild-type cTnI, L144Q had significantly lower maximal ATPase activities than any of the other mutants or wild-type cTnI. Three mutants (L144Q, R145W, and K178E) were unable to fully relax contraction in the absence of Ca2+. The inability of the five cTnI mutations investigated to fully inhibit ATPase activity/force development and the generally larger increases in Ca2+ sensitivity than observed for most hypertrophic cardiomyopathy mutations would likely lead to severe diastolic dysfunction and may be the major physiological factors responsible for causing the restrictive cardiomyopathy phenotype in some of the genetically affected individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961398     DOI: 10.1074/jbc.M500287200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy.

Authors:  Jennifer Davis; Soichiro Yasuda; Nathan J Palpant; Joshua Martindale; Tamara Stevenson; Kimber Converso; Joseph M Metzger
Journal:  J Mol Cell Cardiol       Date:  2012-06-06       Impact factor: 5.000

2.  Dual regulatory functions of the thin filament revealed by replacement of the troponin I inhibitory peptide with a linker.

Authors:  Julie Mouannes Kozaili; Daniel Leek; Larry S Tobacman
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

3.  Low temperature dynamic mapping reveals unexpected order and disorder in troponin.

Authors:  Devanand Kowlessur; Larry S Tobacman
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

4.  Effects of thin and thick filament proteins on calcium binding and exchange with cardiac troponin C.

Authors:  Jonathan P Davis; Catalina Norman; Tomoyoshi Kobayashi; R John Solaro; Darl R Swartz; Svetlana B Tikunova
Journal:  Biophys J       Date:  2007-02-09       Impact factor: 4.033

5.  Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure.

Authors:  Jiang Zhang; Moltu J Guy; Holly S Norman; Yi-Chen Chen; Qingge Xu; Xintong Dong; Huseyin Guner; Sijian Wang; Takushi Kohmoto; Ken H Young; Richard L Moss; Ying Ge
Journal:  J Proteome Res       Date:  2011-07-28       Impact factor: 4.466

6.  Negative charges at protein kinase C sites of troponin I stabilize the inactive state of actin.

Authors:  Mohit C Mathur; Tomoyoshi Kobayashi; Joseph M Chalovich
Journal:  Biophys J       Date:  2007-09-14       Impact factor: 4.033

Review 7.  Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Cardiol       Date:  2007-08       Impact factor: 2.882

8.  The molecular effects of skeletal muscle myosin regulatory light chain phosphorylation.

Authors:  Michael J Greenberg; Tanya R Mealy; James D Watt; Michelle Jones; Danuta Szczesna-Cordary; Jeffrey R Moore
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-05-20       Impact factor: 3.619

9.  Genetic background of Japanese patients with pediatric hypertrophic and restrictive cardiomyopathy.

Authors:  Takeharu Hayashi; Kousuke Tanimoto; Kayoko Hirayama-Yamada; Etsuko Tsuda; Mamoru Ayusawa; Shinichi Nunoda; Akira Hosaki; Akinori Kimura
Journal:  J Hum Genet       Date:  2018-06-15       Impact factor: 3.172

10.  Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments.

Authors:  Brian R Thompson; Joshua Martindale; Joseph M Metzger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-13       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.